On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AbbVie Inc. (NYSE:ABBV) as his final trade.
According to recent news, AbbVie announced on Friday a positive CHMP opinion for MAVIRET® for the treatment of acute hepatitis C infection.
Stephanie Link, chief investment strategist, head of investment solutions and portfolio manager at Hightower Advisors, said Deckers Outdoor Corporation (NYSE:DECK) reported a great quarter and also raised guidance.
Deckers, on May 21, posted fourth-quarter revenue of $1.12 billion, beating analyst estimates of $1.09 billion. The casual footwear and apparel company reported earnings of 96 cents per share for the quarter, beating analyst estimates of 83 cents per share, according to Benzinga Pro.
Don't forget to check out our premarket coverage here
Joseph Terranova, senior managing director, Virtus Investment Partners, recommended The Goldman Sachs Group, Inc. (NYSE:GS).
On May 5, BMO Capital analyst Brennan Hawken maintained Goldman Sachs Group at Market Perform and raised the price target from $905 to $972.
Price Action:
- AbbVie shares fell 1.2% to close at $213.12 on Tuesday.
- Deckers Outdoor jumped 4.5% to settle at $111.44 during the session.
- Goldman Sachs shares slipped 0.2% to close at $994.52 on Tuesday.
Photo via Shutterstock